title: Lomitapide for use in patients with homozygous familial hypercholesterolemia: a narrative review.
abstract: Lomitapide is a drug recently approved for the treatment of patients with homozygous familial hypercholesterolemia. In this article we discuss briefly the pharmacology of this drug followed by a comprehensive narrative review of the available preclinical and clinical data on its safety and efficacy. Only data published as full papers are presented, with the exception of one long-term open-label extension study, which is available only in abstract form.
authors.affiliation: a Center of Endocrinology, Diabetes and Preventive Medicine (ZEDP) , University of Cologne , Cologne , Germany.
authors.forename: Daniela
authors.initials: D
authors.lastname: Neef
authors.affiliation: b Department of Internal Medicine and Geriatrics , Bielefeld Evangelical Hospital (EvKB) , Bielefeld , Germany.
authors.forename: Heiner K
authors.initials: HK
authors.lastname: Berthold
authors.affiliation: a Center of Endocrinology, Diabetes and Preventive Medicine (ZEDP) , University of Cologne , Cologne , Germany.
authors.forename: Ioanna
authors.initials: I
authors.lastname: Gouni-Berthold
mesh_terms: D000924:Anticholesteremic Agents / Q000009:adverse effects / Q000737:chemistry / Q000493:pharmacokinetics / Q000627:therapeutic use*; D001562:Benzimidazoles / Q000009:adverse effects / Q000737:chemistry / Q000493:pharmacokinetics / Q000627:therapeutic use*; D006801:Humans; D006938:Hyperlipoproteinemia Type II / Q000188:drug therapy*; D015394:Molecular Structure
chemical_list: D000924:Anticholesteremic Agents; C473731:BMS201038; D001562:Benzimidazoles
keywords: Lomitapide; MTP inhibitors; cholesterol; familial hypercholesterolemia; lipid-lowering drugs